Vancouver, BC and Ottawa, ON - April 2, 2019: CDRD, Canada’s life sciences venture, TRIUMF, the country’s national particle accelerator centre, and TRIUMF Innovations, the centre’s commercialization arm have joined forces to advance and commercialize promising research in the field of novel radiopharmaceuticals. Speaking at the 11th International Symposium on Targeted Alpha Therapy (TAT 11) in Ottawa, the organizations announced today a new partnership that brings together their respective R&D, manufacturing, and commercialization strengths to develop innovative, personalized cancer treatments.

Please click here for the full press release.